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Perioperative concentrations of serum troponin I (TnI) in the ﬁrst 72h after TAVI were
measured for detection of myocardial injury.
Results: CVR (ﬁg. 1) was impaired at baseline (1.590.37) improved after BAV and
subsequent valve implantation (1.680.37). Recovery time towards bAPV was longer
after the rapid pacing (RP) period during valve implantation than after RP period
during BAV (12.9416.57s vs. 7.969.67s; p¼0.322). A positive correlation was
found between the duration of RP and AUC for perioperative troponin I (p< 0.05).HR
95,0% CI for
Exp(B)
p-valueLower Upper
Gender 1.063 0.678 1.667 0.789
Ejection fraction <40% 1.964 1.118 3.450 0.019
COPD 1.241 0.683 2.255 0.479
Acute MI (<90 days,%) 1.807 1.051 3.106 0.032
Critical perioperative State 2.495 0.875 7.112 0.087
Pulmonary Hypertension 1.520 0.962 2.401 0.073
Renal failure (Creatinine 2.2 mg/dl, %) 2.958 1.591 5.500 0.001
Coronary artery disease 1.040 0.657 1.645 0.868
Previous CABG (%) 1.030 0.566 1.876 0.922
Previous valve surgery 2.297 0.983 5.366 0.055
Diabetes 1.269 0.843 1.911 0.254
Valve type (CoreValve/Sapien) 1.285 0.788 2.096 0.314
New-onset LBBB 1.765 1.160 2.684 0.008Conclusions: TAVI leads to an improvement in CVR,which may pathophysiologi-
cally contribute to attenuation of ischemic symptoms,and a longer RP duration
appears to be associated with myocardial injury.
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Background: The SAPIEN 3 transcatheter heart valve (THV) and its low proﬁle
delivery system (Edwards Lifesciences, CA) incorporate features intended to facilitate
accurate positioning and improve paravalvular sealing.
Methods: A multicenter evaluation of patients implanted with SAPIEN 3 valves was
utilized for this speciﬁc analysis. Optimal pre implantation device position was
deﬁned as position of the lower border of the central marker at the lower border of the
aortic cusps with  1.5mm (i.e.  half central marker length). Implantation images
were evaluated by a dedicated core lab blinded to clinical results.
Results: A total of 143 patients implanted with SAPIEN 3 were included in the study:
56.4% male, age 82.17.7 years, STS score 12.110.1%. Baseline aortic valve area
0.730.26 cm2. All implantations were successful (76.2% transfemoral access),
without malposition or implantation of a second device. Paravalvular regurgitation
was < mild in 95.8%. The rate of major vascular complication was 3.5% and acute
kidney injury 1.4% (VARC 2). At 30 days mortality was 1.4% and major stroke
1.4%. Positioning was optimal in 62 patients and suboptimal in 81. Pre-implantation
depth (lower border of central marker below the line of the cusp border) was
1.062.41mm: 0.20.8mm in cases with optimal position, 3.11.41mm in low-
position and -3.191.36 in those with high-position (p< 0.001). Patients with optimal
device positioning had a lower pacemaker rate than patients with a suboptimal
position (3.2% vs. 18.5%, p¼0.007) and although device size was similar, post im-
plantation aortic valve area was larger (25.92.2mm vs. 25.92.0mm, p¼0.95, and
1.910.49cm2 vs. 1.630.47cm2, p¼0.04, respectively).
Conclusions: This multicenter evaluation suggests that SAPIEN 3 implantation is
associated with excellent results. Clinical outcomes are further improved with optimal
device positioning, according to study deﬁnition.
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Mahlow, BrandenburgJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaBackground: Transcatheter aortic valve implantation is established as a standard
therapy in the treatment of the severe aortic stenosis. Compared with surgical aortic
valve replacement, transcatheter aortic valve implantation (TAVI) is associated with a
higher risk of developing a new conduction disorder that necessitates permanent
pacemaker implantation (PM). The most frequently observed conduction disorder is
left bundle branch block (LBBB). The aim of this study was to establish the predicting
factors of the mid-term all-cause mortality, highlighting the importance of a new-onset
LBBB.
Methods: This study included a total of 634 patients who underwent TAVI with the
Medtronic CoreValve (n¼112) and the Edwards SAPIEN Valve (n¼512) between
May 2008 and April 2012. The effect of demographic parameters and treatment modes
on overall survival were assessed using regression analysis models.
Results: Multivariate regression analyses revealed, that persistent new-onset LBBB
was an independent predictor of all-cause mortality in the one-year follow up (hazard
ratio [HR] 1.77, 95% conﬁdence interval [CI]: 1.16-2.68; p ¼ 0.008). Other inde-
pendent predictors were: renal failure (HR: 2.96, 95% CI: 1.59-5.50; p ¼ 0.001), a left
ventricular ejection fraction of < 40% (HR: 1.96, 95% CI: 1.12-3.45; p ¼ 0.019),
and acute myocardial infarction within 90 days prior to TAVI (HR: 1.81, 95% CI:
1.05-3.11; p ¼ 0.032).Conclusions: This study demonstrated that persistent new-onset LBBB was an in-
dependent predictor of all-cause mortality at the end of the ﬁrst year, along with renal
failure, poor left ventricular ejection fraction and acute myocardial infarction within
90 days prior to TAVI.
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Background: Whether patients with reduced left ventricular function present worse
outcome after transcatheter aortic valve implantation (TAVI) is controversial. The aim
of this study was assess the impact of baseline severe impairment of left ventricular
function on mortality after TAVI.
Methods: Six-hundred-forty-nine patients with aortic stenosis underwent TAVI with
the CoreValve system (92.8%) or the Edwards SAPIEN valve system (7.2%). Base-
line LVEF was measured by the echocardiographic Simpson method. The impact of
LVEF30% on mortality was assessed by Cox regression.
Results: Patients with LVEF 30% (N¼63), as compared to those with LVEF > 30%
(N¼586), had a higher prevalence of NHYA class >2 (p< 0.001) and presented with
a higher Euroscore (p< 0.001). Procedural success was similar in both groups (98.4%
vs 97.2%, p¼1). After a median follow-up of 436 days, all-cause mortality (23.8% vs
23.7%, p¼0.87, HR 0.96, 95% CI 0.56-1.63) and cardiac mortality (19.1% vs 17.6%,
p¼0.89, HR 1.04, 95% CI 0.57-1.90) were similar in patients with LVEF 30% aslvular disease - Aortic: TAVR B211
